Jupiter Neurosciences (NASDAQ: JUNS) awards 525,565 stock options to its CFO

Rhea-AI Filing Summary

JUPITER NEUROSCIENCES, INC. reported a compensation-related stock option grant to its Chief Financial Officer, Saleem Elmasri. He received options for 525,565 shares of common stock at an exercise price of $0.2783 per share, expiring on June 2, 2036.

According to the disclosure, 325,565 options were granted as a discretionary bonus for services during fiscal 2025 and 200,000 options were granted as long-term incentive compensation under the 2025 Equity Incentive Plan. The options vest over three years starting from September 2, 2026 in equal quarterly installments, conditioned on continued employment through each vesting date.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Elmasri Saleem

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option	525,565	$0.00	--

Holdings After Transaction: Stock Option — 525,565 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 525,565 options Exercise price: $0.2783 per share Expiration date: June 2, 2036 +3 more

6 metrics

Options granted 525,565 options Total stock options granted to CFO on June 2, 2026

Exercise price $0.2783 per share Conversion or exercise price of granted options

Expiration date June 2, 2036 Option expiration date

Discretionary bonus options 325,565 options Granted for services rendered during fiscal 2025

Long-term incentive options 200,000 options Granted as long-term incentive compensation

Post-grant derivative holdings 525,565 options Total derivative securities following transaction

Key Terms

2025 Equity Incentive Plan, discretionary bonus, long-term incentive compensation, vesting, +1 more

5 terms

2025 Equity Incentive Plan financial

"options were granted under the Issuer's 2025 Equity Incentive Plan as a discretionary bonus"

discretionary bonus financial

"325,565 options were granted under the Issuer's 2025 Equity Incentive Plan as a discretionary bonus for services"

long-term incentive compensation financial

"200,000 options were granted under the Issuer's 2025 Equity Incentive Plan as long-term incentive compensation"

Long-term incentive compensation is pay awarded to executives or key employees that vests over multiple years and is tied to future company performance, often delivered as stock, options, or multi-year cash bonuses. Think of it as a multi-year reward plan that only pays out if certain goals are met, so it aligns managers’ interests with shareholders. Investors watch it because it affects future costs, share dilution and signals how leadership is motivated to grow value over time.

vesting financial

"The options vest over three years commencing from September 2, 2026 in equal quarterly installments"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Stock Option financial

"security_title: Stock Option"

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Elmasri Saleem

(Last) (First) (Middle)

C/O JUPITER NEUROSCIENCES, INC.

1001 NORTH US HYWAY 1, SUITE 504

(Street)

JUPITER FLORIDA 33477

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
JUPITER NEUROSCIENCES, INC. [ JUNS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$0.2783	06/02/2026		A		525,565		(1)	06/02/2036	Common Stock	525,565	$0	525,565	D

Explanation of Responses:

1. 325,565 options were granted under the Issuer's 2025 Equity Incentive Plan as a discretionary bonus for services rendered during fiscal 2025. 200,000 options were granted under the Issuer's 2025 Equity Incentive Plan as long-term incentive compensation. The options vest over three years commencing from September 2, 2026 in equal quarterly installments subject to continued employment through each vesting date.

	/s/ Saleem Elmasri	06/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did JUNS CFO Saleem Elmasri report in this Form 4 filing?

He reported receiving a stock option grant for 525,565 shares of common stock. The options were issued as compensation under Jupiter Neurosciences’ 2025 Equity Incentive Plan, combining a discretionary bonus and long-term incentive award.

How many stock options did JUNS grant to its CFO and at what exercise price?

Jupiter Neurosciences granted 525,565 stock options to its CFO with an exercise price of $0.2783 per share. These options give him the right to buy company shares at that fixed price before expiration.

How are the 525,565 JUNS stock options for the CFO structured between bonus and long-term incentives?

Of the 525,565 options, 325,565 were granted as a discretionary bonus for fiscal 2025 services and 200,000 as long-term incentive compensation. Both components were issued under the company’s 2025 Equity Incentive Plan.

When do the JUNS CFO’s new stock options start vesting and over what period?

The options begin vesting on September 2, 2026 and vest over three years. Vesting occurs in equal quarterly installments, and each installment requires the CFO to remain employed through the applicable vesting date.

When do the newly granted JUNS stock options to the CFO expire?

The stock options granted to the CFO expire on June 2, 2036. He can only exercise them at the $0.2783 per share exercise price before this expiration date, subject to the vesting and employment conditions.